Literature DB >> 15640322

Asthma: prevalence and cost of illness.

S Stock1, M Redaelli, M Luengen, G Wendland, D Civello, K W Lauterbach.   

Abstract

The purpose of this study was to estimate the prevalence and cost of illness of asthma in Germany by retrospectively analysing routine health insurance data. This analysis investigated claims data from all insured persons of six large sickness funds. Insurants with asthma were identified via the International Classification of Diseases (ninth revision) diagnosis and the Anatomical Therapeutic Chemical Classification System Code for regular medication prescriptions. Costs for hospital care, medication and sick benefit were taken from claims data. Costs for rehabilitation, premature death and early retirement were estimated using the human capital approach and data from national statistics. Prevalence of asthma in the German statutory health insurance was 6.34%. Total costs for asthma, including direct and indirect costs, were calculated at euro 2.74 billion during 1999. The prevalence of asthma in the German statutory health insurance has previously been estimated to be 4-6%. The results of this large study show the prevalence of asthma in the German social insurance system to be approximately 6%. The study also indicates that there is room for substantial savings in the German social insurance system, with indirect costs amounting to 74.8% of total costs and payment of sick benefits through the sickness funds amounting to 58.3% of indirect costs. These costs may be reduced with better asthma control in patients.

Entities:  

Mesh:

Year:  2005        PMID: 15640322     DOI: 10.1183/09031936.04.00116203

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  30 in total

1.  Cost-of-illness studies based on massive data: a prevalence-based, top-down regression approach.

Authors:  Björn Stollenwerk; Thomas Welchowski; Matthias Vogl; Stephanie Stock
Journal:  Eur J Health Econ       Date:  2015-02-04

2.  Prescriptions as a proxy for asthma in children: a good choice?

Authors:  Falk Hoffmann; Gerd Glaeske
Journal:  Eur J Clin Pharmacol       Date:  2010-03       Impact factor: 2.953

Review 3.  Yoga for asthma.

Authors:  Zu-Yao Yang; Hui-Bin Zhong; Chen Mao; Jin-Qiu Yuan; Ya-Fang Huang; Xin-Yin Wu; Yuan-Mei Gao; Jin-Ling Tang
Journal:  Cochrane Database Syst Rev       Date:  2016-04-27

4.  The Effectiveness of Mindfulness Training on Behavioral Problems and Attentional Functioning in Adolescents with ADHD.

Authors:  Eva van de Weijer-Bergsma; Anne R Formsma; Esther I de Bruin; Susan M Bögels
Journal:  J Child Fam Stud       Date:  2011-09-22

5.  Cost and appropriateness of treating asthma with fixed-combination drugs in local health care units in Italy.

Authors:  Isabella Ruggeri; Donatello Bragato; Giorgio L Colombo; Emanuela Valla; Sergio Di Matteo
Journal:  Clinicoecon Outcomes Res       Date:  2012-12-05

Review 6.  Economic burden of asthma: a systematic review.

Authors:  Katayoun Bahadori; Mary M Doyle-Waters; Carlo Marra; Larry Lynd; Kadria Alasaly; John Swiston; J Mark FitzGerald
Journal:  BMC Pulm Med       Date:  2009-05-19       Impact factor: 3.317

7.  Breast cancer attributable costs in Germany: a top-down approach based on sickness funds data.

Authors:  Emil Victor Gruber; Stephanie Stock; Björn Stollenwerk
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

8.  Trends in asthma-related direct medical costs from 2002 to 2007 in British Columbia, Canada: a population based-cohort study.

Authors:  Pierrick Bedouch; Mohsen Sadatsafavi; Carlo A Marra; J Mark FitzGerald; Larry D Lynd
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

Review 9.  Exploring the role and diversity of mucins in health and disease with special insight into non-communicable diseases.

Authors:  Santosh Kumar Behera; Ardhendu Bhusan Praharaj; Budheswar Dehury; Sapna Negi
Journal:  Glycoconj J       Date:  2015-08-04       Impact factor: 3.009

10.  Bidirectional Counterregulation of Human Lung Mast Cell and Airway Smooth Muscle β2 Adrenoceptors.

Authors:  Rebecca J Lewis; Latifa Chachi; Chris Newby; Yassine Amrani; Peter Bradding
Journal:  J Immunol       Date:  2015-11-25       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.